Abstract: Disclosed are compounds of formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, U, W, X, R1, R2, R6, R7, R30 and R31 are as described above in the specification. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

Abstract: A test system and method utilizing a single storage device through a network, which includes a server and at least a test object connected to a storage device that supports multi-system operations. The storage device provides many kinds of test environments and test tools for different test objects. The storage device includes a test program, a plurality of virtual test sections and test tools. When a correspondent virtual test section does not exist in the storage device, the associated test disk image is obtained from the server for establishing a new virtual test section in the storage device. Through the network operation, the test environment management is simplified and the test efficiency is improved.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.

Abstract: The present invention discloses compounds, which are novel receptor antagonists for NPY Y1 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y1 receptor antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

Abstract: The present invention is directed to certain diaryl amide compounds as NS3-Serine protease inhibitors of hepatitis C virus.

Abstract: A DTD-compliant XML document editor is disclosed. The XML document editor generates hints for required elements and required element slots automatically in the process of document creation and edition so as to guide the user to produce a valid document, while syntactic violations are avoided at the same time. The editor also suggests optional elements that may be added into the document to be edited. The user requires no knowledge about XML and DTD to edit DTD-compliant XML documents. The editing process is user-interface-neutral, being able to support user interfaces based on tree views, presentation views and forms. By combining the DTD-compliant editing process with the simplicity of forms, a simple XML document editor with forms as its user interface is developed.

Abstract: A test system and method utilizing a single storage device through a network, which includes a server and at least a test object connected to a storage device that supports multi-system operations. The storage device provides many kinds of test environments and test tools for different test objects. The storage device includes a test program, a plurality of virtual test sections and test tools. When a correspondent virtual test section does not exist in the storage device, the associated test disk image is obtained from the server for establishing a new virtual test section in the storage device. Through the network operation, the test environment management is simplified and the test efficiency is improved.

Abstract: A device and method are provided for producing negatively charged nanoparticles. The device comprises a power supply, an electron supermicroemitter and a controller, the power supply connects with the electron supermicroemitter and the controller respectively. The potential of the electron supermicroemitter to the ground is controlled in the range of −2 kV to −29 kV by the power supply and the controller in accordance with the shape, size and different application of the materials of the emitter, so as to form field electron emitting of tunneling effect. The energy of electrons with high current density produced by the emitter can be adjusted during the electrons' colliding with particles in aerosol such that the electrons are attached to the nanoparticles of different size with wider energy band to form negatively charged nanoparticles.

Abstract: The present invention is directed to certain diaryl amide compounds as NS3-Serine protease inhibitors of hepatitis C virus.